Short summary

In 2024, all dermatological patients undergoing methotrexate therapy were evaluated paraclinically using the liver fibrosis markers FIB-4 and P3NP. Patients with abnormal FIB-4 results subsequently underwent hepatic ultrasound examination. This study aims to compare the diagnostic performance of the two fibrosis markers.

Rationale

This study aims to evaluate the sensitivity of the liver fibrosis biomarkers FIB-4 and P3NP in dermatological patients undergoing methotrexate therapy. All patients were assessed using both markers in 2024. Patients with abnormal FIB-4 values underwent hepatic ultrasound. The objective is to determine whether FIB-4 alone can reliably identify patients at risk of liver fibrosis, thereby potentially reducing the number of patients requiring ultrasound examination.

Description of the cohort

All adult patients undergoing treatment with methotrexate at the department of dermatology at Odense University Hospital in 2024.

Data and biological material

Patient records were reviewed for: Demographics (age, sex) Diagnosis and methotrexate dosage/duration FIB-4 and P3NP values Ultrasound findings (if performed) Liver function tests and comorbidities

Collaborating researchers and departments

Department of Dermatology and Allergy Centre

• Consultant Mathias Tiedemann Svendsen

Publications associated with the project

Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015 Nov 7;21(41):11567-83.